Gewählte Publikation:
SHR
Neuro
Krebs
Kardio
Lipid
Stoffw
Microb
Shahid, GB; Ahan, RE; Ostaku, J; Seker, UOS.
Bacterial Living Therapeutics with Engineered Protein Secretion Circuits to Eliminate Breast Cancer Cells.
ACS Synth Biol. 2024; 13(10): 3150-3162.
Doi: 10.1021/acssynbio.3c00723
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
-
Ostaku Julian
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Cancer therapy can be limited by potential side effects, and bacteria-based living cancer therapeutics have gained scientific interest in recent years. However, the full potential of bacteria as therapeutics has yet to be explored due to engineering challenges. In this study, we present a bacterial device designed to specifically target and eliminate breast cancer cells. We have engineered Escherichia coli (E. coli) to bind to HER2 receptors on breast cancer cells while also secreting a toxin, HlyE, which is a pore-forming protein. The binding of E. coli to HER2 is facilitated by a nanobody expressed on the bacteria's surface via the Ag43 autotransporter protein system. Our findings demonstrate that the nanobody efficiently binds to HER2+ cells in vitro, and we have utilized the YebF secretion tag to secrete HlyE and kill the target cancer cells. Overall, our results highlight the potential of our engineered bacteria as an innovative strategy for breast cancer treatment.
- Find related publications in this database (using NLM MeSH Indexing)
-
Breast Neoplasms - metabolism, genetics, pathology
-
Humans - administration & dosage
-
Escherichia coli - metabolism, genetics
-
Female - administration & dosage
-
Receptor, ErbB-2 - metabolism, genetics
-
Cell Line, Tumor - administration & dosage
-
Escherichia coli Proteins - metabolism, genetics
-
Single-Domain Antibodies - metabolism
-
Protein Engineering - methods
- Find related publications in this database (Keywords)
-
living therapeutics
-
cancer therapeutics
-
syntheticbiology